Fulcrum Therapeutics disclosed on June 1, 2026 that it discontinued pociredir for sickle cell disease, triggering a stock decline. A securities-law inquiry from Holzer & Holzer followed, though the release emphasizes investigation rather than a filed suit. The development adds regulatory and pipeline risk, potentially pressuring valuation until clarity on the program's status and any impact on cash flow emerges.
Fulcrum Therapeutics halted its sickle-cell therapy program after the FDA raised cancer-risk concerns, closing the regulatory path. The setback heightens execution risk, potentially triggering impairment charges and a strategic pivot as the company reassesses its cash runway. Investors may now focus on alternative assets within the pipeline and balance-sheet options.
